Anne Hansen Ree

• Mecinaj, Albulena; Gulati, Geeta; Ree, Anne Hansen; Gravdehaug, Berit; Røsjø, Helge Rørvik & Steine, Kjetil [Vis alle 10 forfattere av denne artikkelen] (2024). Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy–Related Cardiac Dysfunction. JACC: CardioOncology. ISSN 2666-0873. 6(1), s. 83–95. doi: 10.1016/j.jaccao.2023.10.008.
• Knuth, Franziska; Tohidinezhad, Fariba; Winter, Rene Mario; Bakke, Kine Mari; Negård, Anne & Holmedal, Stein Harald [Vis alle 10 forfattere av denne artikkelen] (2024). Quantitative MRI-based radiomics analysis identifies blood flow feature associated to overall survival for rectal cancer patients. Scientific Reports. ISSN 2045-2322. 14(1). doi: 10.1038/s41598-023-50966-9.
• Nygaard, Vigdis; Ree, Anne Hansen; Dagenborg, Vegar Johansen; Børresen-Dale, Anne-Lise; Edwin, Bjørn von Gohren & Fretland, Åsmund Avdem [Vis alle 10 forfattere av denne artikkelen] (2023). A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases. Cancer Research Communications. ISSN 2767-9764. 3(2), s. 235–244. doi: 10.1158/2767-9764.CRC-22-0295. Fulltekst i vitenarkiv
• Bjørnetrø, Tonje; Bousquet, Paula; Redalen, Kathrine Røe; Siebke, Anne-Marie; Lüders, Torben & Stang, Espen [Vis alle 12 forfattere av denne artikkelen] (2023). Next-generation sequencing reveals mitogenome diversity in plasma extracellular vesicles from colorectal cancer patients. BMC Cancer. ISSN 1471-2407. 23(1). doi: 10.1186/s12885-023-11092-x. Fulltekst i vitenarkiv
• Larsen, Trine-Lise; Svalastoga, Marte; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege & Garresori, Herish [Vis alle 16 forfattere av denne artikkelen] (2023). Arterial events in cancer patients treated with apixaban for venous thrombosis. Thrombosis Research. ISSN 0049-3848. 228, s. 128–133. doi: 10.1016/j.thromres.2023.05.017.
• Høye, Eirik; Dagenborg, Vegar Johansen; Kristensen, Annette Torgunrud; Lund-Andersen, Christin; Fretland, Åsmund Avdem & Lorenz, Susanne [Vis alle 13 forfattere av denne artikkelen] (2023). T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases. GigaScience. ISSN 2047-217X. 12. doi: 10.1093/gigascience/giad032. Fulltekst i vitenarkiv
• Buckley, Croí E.; Yin, Xiaofei; Meltzer, Sebastian; Ree, Anne Hansen; Redalen, Kathrine Røe & Brennan, Lorraine [Vis alle 8 forfattere av denne artikkelen] (2023). Energy Metabolism Is Altered in Radioresistant Rectal Cancer. International Journal of Molecular Sciences. ISSN 1661-6596. 24(8). doi: 10.3390/ijms24087082. Fulltekst i vitenarkiv
• Bakke, Kine Mari; Meltzer, Sebastian; Grøvik, Endre; Negård, Anne; Holmedal, Stein Harald & Mikalsen, Lars Tore Gyland [Vis alle 13 forfattere av denne artikkelen] (2023). Imaging the tumour microenvironment in rectal cancer: Decline in tumour blood flow during radiotherapy predicts good outcome. Physics and imaging in radiation oncology (PIRO). ISSN 2405-6316. 25, s. 1–7. doi: 10.1016/j.phro.2023.100417. Fulltekst i vitenarkiv Vis sammendrag

  Background and purpose Measuring rectal tumour response to radiation is pivotal to restaging patients and for possibly stratification to a watch-and-wait strategy. Recognizing the importance of the tumour microenvironment, we investigated a less explored quantitative imaging marker assessing tumour blood flow (BF) for its potential to predict overall survival (OS). Materials and methods 24 rectal cancer patients given curative-intent neoadjuvant radiotherapy underwent a multi-echo dynamic magnetic resonance imaging (MRI) sequence with gadolinium contrast for quantification of tumour BF before either 25x2 Gy (n = 18) with concomitant chemotherapy or 5x5 Gy (n = 6). CD34 staining of excised tumour tissue was performed and baseline blood samples were analysed for lactate dehydrogenase (LDH) and angiopoietin-2 (ANGPT-2). Tumour volumes were measured before and after treatment. After subsequent surgery, ypTN scoring assessed tumour response. Cox regression for 5-year OS analysis and t-test for group comparisons were performed. Results The change in tumour BF (ΔBF) during neoadjuvant radiotherapy was a significant marker of OS, whereas tumour stage and volume were not related to OS. All patients with >20 % decline in BF were long-term survivors. Separating cases in two groups based on ΔBF revealed that patients with increase or a low decrease had higher baseline LDH (p = 0.032) and ANGPT-2 (p = 0.028) levels. Conclusion MRI-assessed tumour ΔBF during neoadjuvant treatment is a significant predictor of OS in rectal cancer patients, making ΔBF a potential quantitative imaging biomarker for treatment stratification. Blood LDH and ANGPT-2 indicate that non-responding tumours may have a hypoxic microenvironment resistant to radiotherapy.

• Fuglestad, Anniken Jørlo; Meltzer, Sebastian; Ree, Anne Hansen; McMillan, Donald C.; Park, James H. & Kersten, Christian (2022). The clinical value of C-reactive protein and its association with tumour location in patients undergoing curative surgery for colorectal cancer–a ScotScan collaborative study. Acta Oncologica. ISSN 0284-186X. 61(10), s. 1248–1255. doi: 10.1080/0284186X.2022.2117572. Fulltekst i vitenarkiv
• Meltzer, Sebastian; Negård, Anne; Bakke, Kine Mari; Hamre, Hanne Mari; Kersten, Christian & Hofsli, Eva [Vis alle 10 forfattere av denne artikkelen] (2022). Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer. British Journal of Cancer. ISSN 0007-0920. 127, s. 2227–2233. doi: 10.1038/s41416-022-02004-0. Fulltekst i vitenarkiv
• Malenge, Marion Masitsa; Maaland, Astri Fjelde; Repetto-Llamazares, Ada H.V.; Middleton, Brian; Nijland, Marcel & Visser, Lydia [Vis alle 12 forfattere av denne artikkelen] (2022). Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro. PLOS ONE. ISSN 1932-6203. 17(4). doi: 10.1371/journal.pone.0267543. Fulltekst i vitenarkiv Vis sammendrag

  Background and purpose: PARP inhibitors have been shown to increase the efficacy of radiotherapy in preclinical models. Radioimmunotherapy results in selective radiation cytotoxicity of targeted tumour cells. Here we investigate the combined effect of anti-CD37 β-emitting 177Lu-NNV003 radioimmunotherapy and the PARP inhibitor olaparib, and gene expression profiles in CD37 positive non-Hodgkin's lymphoma cell lines. Materials and methods: The combined effect of 177Lu-NNV003 and olaparib was studied in seven cell lines using a fixed-ratio ray design, and combination index was calculated for each combination concentration. mRNA was extracted before and after treatment with the drug combination. After RNA-sequencing, hierarchical clustering was performed on basal gene expression profiles and on differentially expressed genes after combination treatment from baseline. Functional gene annotation analysis of significant differentially expressed genes after combination treatment was performed to identify enriched biological processes. Results: The combination of olaparib and 177Lu-NNV003 was synergistic in four of seven cell lines, antagonistic in one and both synergistic and antagonistic (conditionally synergistic) in two, depending on the concentration ratio between olaparib and 177Lu-NNV003. Cells treated with the combination significantly overexpressed genes in the TP53 signalling pathway. However, cluster analysis did not identify gene clusters that correlate with the sensitivity of cells to single agent or combination treatment. Conclusion: The cytotoxic effect of the combination of the PARP inhibitor olaparib and the β-emitting radioimmunoconjugate 177Lu-NNV003 was synergistic in the majority of tested lymphoma cell lines.

• Ree, Anne Hansen; Mælandsmo, Gunhild Mari; Flatmark, Kjersti; Russnes, Hege Elisabeth Giercksky; Casteneda, Monica Gomez & Aas, Eline (2022). Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer – the MetAction precision medicine study. Acta Oncologica. ISSN 0284-186X. 61(8), s. 955–962. doi: 10.1080/0284186X.2022.2098053. Fulltekst i vitenarkiv
• Ambrosini, Margherita; Del Re, Marzia; Manca, Paolo; Hendifar, Andrew; Drilon, Alexander & Harada, Guilherme [Vis alle 21 forfattere av denne artikkelen] (2022). ALK Inhibitors in Patients with ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series. JCO Precision Oncology (JCO PO). 6(1). doi: 10.1200/PO.22.00015. Fulltekst i vitenarkiv Vis sammendrag

  PURPOSE In GI cancers, anaplastic lymphoma kinase (ALK) rearrangements are extremely less frequent than in non–small-cell lung cancer but may be important to offer personalized strategies of treatment in selected patients. Data about the activity and efficacy of ALK inhibitors (ALKi) in GI cancers are scarce. MATERIALS AND METHODS We assembled a clinical and molecular international data set of pretreated patients with metastatic or nonresectable cancers of GI primary tumor origin with documented ALK rearrangement treated with at least one line of ALKi. Measurable disease as per RECIST 1.1 was required for response analysis. RESULTS Primary tumor sites were distributed as follows: 5 (38%) pancreas, 3 (23%) right colon, and 1 (8%) for each one of gastric, duodenal, rectal, left colon, and biliary tract sites. Seven patients (54%) were treated with alectinib, 5 (38%) with crizotinib, and 1 (8%) with entrectinib. After disease progression, five patients (38%) received a subsequent ALKi treatment line, and at the time of data cutoff date, treatment was still ongoing in two patients. Five of 12 evaluable patients (41%) achieved a partial response to first-line ALKi, five patients (41%) had stable disease, and 2 (17%) had progressive disease. No complete responses were registered. At a median follow-up of 39.6 months (interquartile range: 19.8-59.5), the median progression-free survival was 5.0 months (95% CI, 3.68 to no response) and the median overall survival was 9.3 months (95% CI, 5.46 to no response). CONCLUSION Treatment with ALKi provides remarkable responses and clinical benefit in pretreated patients with ALK fusion–positive GI malignancies. Despite the rarity, ALK rearrangements represent an important therapeutic target in individual pretreated patients with GI solid tumors. Further work providing prospective clinical validation of this target is needed.

• Larsen, Trine-Lise; Garresori, Herish; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege & Jacobsen, Eva-Marie [Vis alle 15 forfattere av denne artikkelen] (2022). Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow-up. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 20(5), s. 1166–1181. doi: 10.1111/jth.15666. Fulltekst i vitenarkiv Vis sammendrag

  Background There are no data on the effect of low-dose anticoagulation as secondary prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy and safety of low-dose apixaban for 30 months, after initial 6 months of full-dose treatment. Methods We included 298 patients with cancer and any type of VTE in a single arm interventional clinical trial. All patients were treated with full-dose apixaban (5 mg twice daily) for 6 months. Total 196 patients with active cancer after 6 months treatment continued with apixaban 2.5 mg twice daily for another 30 months. The main endpoints were recurrent VTE, major bleeding and clinically relevant non-major bleeding. Results During the 30 months of treatment with low-dose apixaban 14 (7.6%; 95% confidence interval (CI) 4.0%–11.7%) patients experienced recurrent VTE, six (3.1%; 95% CI 1.1%–6.5%) experienced major bleeding and 16 (8.1%, 95% CI: 4.7%–12.8%) experienced clinically relevant non-major bleeding. The incidence rate per person month of recurrent VTE was 0.8% (95% CI 0.41–1.6) at 2–6 months with full-dose apixaban, and 1.0% (95% CI 0.5–1.9) at 7–12 months with low-dose apixaban. The incidence rate of major bleeding was 1.1% (95% CI 0.6–2.0) at 2–6 months, and 0.3% (95% CI 0.1–1.0) at 7–12 months. Between 12 and 36 months the incidence rate of recurrent VTE and major bleedings remained low. Conclusion Dose reduction of apixaban to 2.5 mg twice daily seems safe after 6 months of full-dose treatment. After 12 months the incidence rate of recurrent VTE and major bleeding remained low.

• Bousquet, Paula; Meltzer, Sebastian; Fuglestad, Anniken Jørlo; Lüders, Torben; Esbensen, Qin Ying & Juul, Hedvig Vidarsdotter [Vis alle 13 forfattere av denne artikkelen] (2021). The mitochondrial DNA constitution shaping T-cell immunity in patients with rectal cancer at high risk of metastatic progression. Clinical and Translational Oncology. ISSN 1699-048X. doi: 10.1007/s12094-021-02756-w. Fulltekst i vitenarkiv
• Knuth, Franziska Hanna; Adde, Ingvild Askim; Huynh, Bao Ngoc; Grøndahl, Aurora Rosvoll; Winter, René & Negård, Anne [Vis alle 15 forfattere av denne artikkelen] (2021). MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts. Acta Oncologica. ISSN 0284-186X. 61(2), s. 255–263. doi: 10.1080/0284186X.2021.2013530. Fulltekst i vitenarkiv
• Dagenborg, Vegar Johansen; Marshall, Serena; Grzyb, Krzysztof; Fretland, Åsmund Avdem; Lund-Iversen, Marius & Mælandsmo, Gunhild Mari [Vis alle 10 forfattere av denne artikkelen] (2021). Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer. Frontiers in Oncology. ISSN 2234-943X. 11, s. 1–9. doi: 10.3389/fonc.2021.671629. Fulltekst i vitenarkiv
• Heck, Siri Lagethon; Mecinaj, Albulena; Ree, Anne Hansen; Hoffmann, Pavel; Schulz-Menger, Jeanette & Fagerland, Morten [Vis alle 12 forfattere av denne artikkelen] (2021). Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): Extended follow-up of a 2×2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation. ISSN 0009-7322. 143(25), s. 2431–2440. doi: 10.1161/CIRCULATIONAHA.121.054698. Fulltekst i vitenarkiv
• Meltzer, Sebastian; Kristensen, Annette Torgunrud; Abrahamsson, Hanna Josefine; Solbakken, Arne Mide; Flatmark, Kjersti & Dueland, Svein [Vis alle 15 forfattere av denne artikkelen] (2021). The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer. British Journal of Cancer. ISSN 0007-0920. 125, s. 240–246. doi: 10.1038/s41416-021-01377-y. Fulltekst i vitenarkiv
• Abrahamsson, Hanna Josefine; Meltzer, Sebastian; Hagen, Vidar Nyløkken; Johansen, Christin; Bousquet, Paula & Redalen, Kathrine [Vis alle 7 forfattere av denne artikkelen] (2021). Sex disparities in vitamin D status and the impact on systemic inflammation and survival in rectal cancer. BMC Cancer. ISSN 1471-2407. 21. doi: 10.1186/s12885-021-08260-2. Fulltekst i vitenarkiv
• Bjørnetrø, Tonje; Steffensen, Lilly Alice; Vestad, Beate; Brusletto, Berit Sletbakk; Olstad, Ole Kristoffer & Siebke, Anne-Marie [Vis alle 15 forfattere av denne artikkelen] (2021). Uptake of circulating extracellular vesicles from rectal cancer patients and differential responses by human monocyte cultures. FEBS Open Bio. ISSN 2211-5463. 11(3), s. 724–740. doi: 10.1002/2211-5463.13098. Fulltekst i vitenarkiv
• Dagenborg, Vegar Johansen; Marshall, Serena Elizabeth; Grzyb, Krzysztof; Fretland, Åsmund Avdem; Lund-Iversen, Marius & Mælandsmo, Gunhild Mari [Vis alle 10 forfattere av denne artikkelen] (2020). Low concordance between T-cell densities in matched primary tumors and liver metastases in microsatellite stable colorectal cancer. Frontiers in Oncology. ISSN 2234-943X. 11.
• Dagenborg, Vegar Johansen; Marshall, Serena; Yaqub, Sheraz; Grzyb, Krzysztof; Pedersen, Kjetil Boye & Lund-Iversen, Marius [Vis alle 12 forfattere av denne artikkelen] (2020). Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases. Cancer Biology & Therapy. ISSN 1538-4047. 21(5), s. 432–440. doi: 10.1080/15384047.2020.1721252. Fulltekst i vitenarkiv
• Meltzer, Sebastian; Bjørnetrø, Tonje; Lyckander, Lars Gustav; Flatmark, Kjersti; Dueland, Svein & Samiappan, Rampradeep [Vis alle 10 forfattere av denne artikkelen] (2020). Corrigendum to “Circulating exosomal miR-141-3p and miR-375 in metastatic progression of rectal cancer” [Transl Oncol 12 (8) (2019) 1038-1044]. Translational Oncology. ISSN 1944-7124. 133(1), s. 122–124. doi: 10.1016/j.tranon.2019.09.005. Fulltekst i vitenarkiv
• Hannevik, Trine-Lise; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege; Ahmed, Herish & Jacobsen, Eva-Marie [Vis alle 15 forfattere av denne artikkelen] (2020). Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism. Thrombosis Research. ISSN 0049-3848. 196, s. 238–244. doi: 10.1016/j.thromres.2020.08.042.
• Bakke, Kine Mari; Meltzer, Sebastian; Grøvik, Endre; Negård, Anne; Holmedal, Stein Harald & Gjesdal, Kjell-Inge [Vis alle 9 forfattere av denne artikkelen] (2020). Sex differences and tumor blood flow from dynamic susceptibility contrast MRI are associated with treatment response after chemoradiation and long-term survival in rectal cancer. Radiology. ISSN 0033-8419. 297(2), s. 352–360. doi: 10.1148/RADIOL.2020200287. Fulltekst i vitenarkiv Vis sammendrag

  Sex differences, tumor vascularity, and blood flow seen on multiecho dynamic contrast–based MRI scans enabled prediction of treatment response and overall survival in patients with rectal cancer. Background: MRI is the standard tool for rectal cancer staging. However, more precise diagnostic tests that can assess biologic tumor features decisive for treatment outcome are necessary. Tumor perfusion and hypoxia are two important features; however, no reference methods that measure these exist in clinical use. Purpose: To assess the potential predictive and prognostic value of MRI-assessed rectal cancer perfusion, as a surrogate measure of hypoxia, for local treatment response and survival. Materials and Methods: In this prospective observational cohort study, 94 study participants were enrolled from October 2013 to December 2017 (ClinicalTrials.gov: NCT01816607). Participants had histologically confirmed rectal cancer and underwent routine diagnostic MRI, an extended diffusion-weighted sequence, and a multiecho dynamic contrast agent–based sequence. Predictive and prognostic values of dynamic contrast-enhanced, dynamic susceptibility contrast (DSC), and intravoxel incoherent motion MRI were investigated with response to neoadjuvant treatment, progression-free survival, and overall survival as end points. Secondary objectives investigated potential sex differences in MRI parameters and relationship with lymph node stage. Statistical methods used were Cox regression, Student t test, and Mann-Whitney U test.Results: A total of 94 study participants (mean age, 64 years ± 11 [standard deviation]; 61 men) were evaluated. Baseline tumor blood flow from DSC MRI was lower in patients who had poor local tumor response to neoadjuvant treatment (96 mL/min/100 g ± 33 for ypT2–4, 120 mL/min/100 g ± 21 for ypT0–1; P = .01), shorter progression-free survival (hazard ratio = 0.97; 95% confidence interval: 0.96, 0.98; P < .001), and shorter overall survival (hazard ratio = 0.98; 95% confidence interval: 0.98, 0.99; P < .001). Women had higher blood flow (125 mL/min/100 g ± 27) than men (74 mL/min/100 g ± 26, P < .001) at stage 4. Volume transfer constant and plasma volume from dynamic contrast-enhanced MRI as well as ΔR2* peak and area under the curve for 30 and 60 seconds from DSC MRI were associated with local malignant lymph nodes (pN status). Median area under the curve for 30 seconds was 0.09 arbitrary units (au) ± 0.03 for pN1–2 and 0.19 au ± 0.12 for pN0 (P = .001). Conclusion:Low tumor blood flow from dynamic susceptibility contrast MRI was associated with poor treatment response in study participants with rectal cancer.

• Malenge, Marion Masitsa; Patzke, Sebastian; Ree, Anne Hansen; Stokke, Trond; Ceuppens, Peter & Middleton, Brian [Vis alle 8 forfattere av denne artikkelen] (2020). 177Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin lymphoma. Journal of Nuclear Medicine. ISSN 0161-5505. 61(10), s. 1468–1475. doi: 10.2967/jnumed.119.237230. Fulltekst i vitenarkiv
• Kalanxhi, Ert; Meltzer, Sebastian & Ree, Anne Hansen (2020). Immune-modulating effects of conventional therapies in colorectal cancer. Cancers. ISSN 2072-6694. 12:2193(8), s. 1–22. doi: 10.3390/cancers12082193. Fulltekst i vitenarkiv
• Ree, Anne Hansen; Nygaard, Vigdis; Pedersen, Kjetil Boye; Heinrich, Daniel; Dueland, Svein & Bergheim, Inger Riise [Vis alle 25 forfattere av denne artikkelen] (2020). Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer?the MetAction study. Acta Oncologica. ISSN 0284-186X. s. 1–10. doi: 10.1080/0284186X.2020.1742377. Fulltekst i vitenarkiv
• Abrahamsson, Hanna Josefine; Jensen, Benny Vittrup; Berven, Lise; Nielsen, Dorte Lisbet; Saltyte-Benth, Jurate & Johansen, Jakob Sidenius [Vis alle 9 forfattere av denne artikkelen] (2019). Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation: 8-12 years of follow-up. International Journal of Cancer. ISSN 0020-7136. doi: 10.1002/ijc.32847. Fulltekst i vitenarkiv
• Bains, Simer Jit; Abrahamsson, Hanna Josefine; Flatmark, Kjersti; Dueland, Svein; Hole, Knut Håkon & Seierstad, Therese [Vis alle 9 forfattere av denne artikkelen] (2019). Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer. Cancer Immunology and Immunotherapy. ISSN 0340-7004. doi: 10.1007/s00262-019-02458-x. Fulltekst i vitenarkiv
• Meltzer, Sebastian; Bakke, Kine Mari; Rød, Karina Lund; Negård, Anne; Flatmark, Kjersti & Solbakken, Arne Mide [Vis alle 19 forfattere av denne artikkelen] (2019). Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors? Clinical and Translational Radiation Oncology. ISSN 2405-6308. 21, s. 5–10. doi: 10.1016/j.ctro.2019.11.006. Fulltekst i vitenarkiv
• Flørenes, Vivi Ann; Flem-Karlsen, Karine; McFadden, Erin; Bergheim, Inger Riise; Nygaard, Vigdis & Nygård, Vegard Mokleiv [Vis alle 17 forfattere av denne artikkelen] (2019). A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Translational Oncology. ISSN 1944-7124. 12(7), s. 951–958. doi: 10.1016/j.tranon.2019.04.001. Fulltekst i vitenarkiv
• Ree, Anne Hansen; Nygaard, Vigdis; Russnes, Hege Elisabeth Giercksky; Heinrich, Daniel; Nygaard, Vegard & Johansen, Christin [Vis alle 13 forfattere av denne artikkelen] (2019). Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain. Cancer immunology research. ISSN 2326-6066. 7(5), s. 701–706. doi: 10.1158/2326-6066.CIR-18-0777. Fulltekst i vitenarkiv
• Bakke, Kine Mari; Grøvik, Endre; Meltzer, Sebastian; Negård, Anne; Holmedal, Stein Harald & Mikalsen, Lars Tore G [Vis alle 11 forfattere av denne artikkelen] (2019). Comparison of Intravoxel incoherent motion imaging and multiecho dynamic contrast-based MRI in rectal cancer. Journal of Magnetic Resonance Imaging. ISSN 1053-1807. 50(4), s. 1114–1124. doi: 10.1002/jmri.26740. Fulltekst i vitenarkiv Vis sammendrag

  Background Dynamic contrast‐based MRI and intravoxel incoherent motion imaging (IVIM) MRI are both methods showing promise as diagnostic and prognostic tools in rectal cancer. Both methods aim at measuring perfusion‐related parameters, but the relationship between them is unclear. Purpose To investigate the relationship between perfusion‐ and permeability‐related parameters obtained by IVIM‐MRI, T1‐weighted dynamic contrast‐enhanced (DCE)‐MRI and T2*‐weighted dynamic susceptibility contrast (DSC)‐MRI. Study Type Prospective. Subjects In all, 94 patients with histologically confirmed rectal cancer. Field Strength/Sequence Subjects underwent pretreatment 1.5T clinical procedure MRI, and in addition a study‐specific diffusion‐weighted sequence (b = 0, 25, 50, 100, 500, 1000, 1300 s/mm2) and a multiecho dynamic contrast‐based echo‐planer imaging sequence. Assessment Median tumor values were obtained from IVIM (perfusion fraction [f], pseudodiffusion [D*], diffusion [D]), from the extended Tofts model applied to DCE data (Ktrans, kep, vp, ve) and from model free deconvolution of DSC (blood flow [BF] and area under curve). A subgroup of the excised tumors underwent immunohistochemistry with quantification of microvessel density and vessel size. Statistical Test Spearman's rank correlation test. Results D* was correlated with BF (rs = 0.47, P < 0.001), and f was negatively correlated with kep (rs = –0.31, P = 0.002). BF was correlated with Ktrans (rs = 0.29, P = 0.004), but this correlation varied extensively when separating tumors into groups of low (rs = 0.62, P < 0.001) and high (rs = –0.06, P = 0.68) BF. Ktrans was negatively correlated with vessel size (rs = –0.82, P = 0.004) in the subgroup of tumors with high BF. Data Conclusion We found an association between D* from IVIM and BF estimated from DSC‐MRI. The relationship between IVIM and DCE‐MRI was less clear. Comparing parameters from DSC‐MRI and DCE‐MRI highlights the importance of the underlying biology for the interpretation of these parameters. Level of Evidence: 2 Technical Efficacy: Stage 1

• Abrahamsson, Hanna Josefine; Porojnicu, Alina Carmen; Lindstrøm, Jonas Christoffer; Dueland, Svein; Flatmark, Kjersti & Hole, Knut Håkon [Vis alle 11 forfattere av denne artikkelen] (2019). High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer. BMC Cancer. ISSN 1471-2407. 19(1). doi: 10.1186/s12885-019-5724-z. Fulltekst i vitenarkiv
• Meltzer, Sebastian; Bjørnetrø, Tonje; Lyckander, Lars Gustav; Flatmark, Kjersti; Dueland, Svein & Samiappan, Rampradeep [Vis alle 10 forfattere av denne artikkelen] (2019). Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer. Translational Oncology. ISSN 1944-7124. 12(8), s. 1038–1044. doi: 10.1016/j.tranon.2019.04.014. Fulltekst i vitenarkiv
• Bjørnetrø, Tonje; Redalen, Kathrine; Meltzer, Sebastian; Thusyanthan, Nirujah Sivarajah; Samiappan, Rampradeep & Jegershöld, Caroline [Vis alle 8 forfattere av denne artikkelen] (2019). An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer. Journal of Extracellular Vesicles. ISSN 2001-3078. 8(1). doi: 10.1080/20013078.2019.1567219. Fulltekst i vitenarkiv
• Bousquet, Paula; Meltzer, Sebastian; Sønstevold, Linda; Esbensen, Qin Ying; Dueland, Svein & Flatmark, Kjersti [Vis alle 12 forfattere av denne artikkelen] (2018). Markers of mitochondrial metabolism in tumor hypoxia, systemic inflammation, and adverse outcome of rectal cancer. Translational Oncology. ISSN 1944-7124. 12(1), s. 76–83. doi: 10.1016/j.tranon.2018.09.010. Fulltekst i vitenarkiv
• Boysen, Anders Kindberg; Sørensen, Boe Sandahl; Lefevre, Anna C.; Abrantes, Rafaela; Johansen, Julia Sidenius & Jensen, Benny Vittrup [Vis alle 17 forfattere av denne artikkelen] (2018). Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer. Clinica Chimica Acta. ISSN 0009-8981. 487, s. 107–111. doi: 10.1016/j.cca.2018.09.029.
• Gopinathan, Unni; Redalen, Kathrine; Siebke, Anne-Marie; Kierulf, Peter; Brandtzæg, Petter & Ree, Anne Hansen [Vis alle 8 forfattere av denne artikkelen] (2018). Large-scale reduction of tyrosine kinase activities in human monocytes stimulated in vitro with N. meningitidis. PLOS ONE. ISSN 1932-6203. 13(1). doi: 10.1371/journal.pone.0181912. Fulltekst i vitenarkiv
• Kalanxhi, Ert; Meltzer, Sebastian; Schou, Jakob Vasehus; Larsen, Finn Ole; Dueland, Svein & Flatmark, Kjersti [Vis alle 12 forfattere av denne artikkelen] (2018). Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. British Journal of Cancer. ISSN 0007-0920. 118(10), s. 1322–1328. doi: 10.1038/s41416-018-0085-y. Fulltekst i vitenarkiv
• Heck, Siri Lagethon; Gulati, Geeta; HOFFMANN, PAVEL; von Knobelsdorff-Brenkenhoff, Florian; Storås, Tryggve & Ree, Anne Hansen [Vis alle 12 forfattere av denne artikkelen] (2018). Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: The PRADA trial. European Heart Journal-Cardiovascular Imaging. ISSN 2047-2404. 19(5), s. 544–552. doi: 10.1093/ehjci/jex159. Fulltekst i vitenarkiv Vis sammendrag

  Aims: Anthracycline treatment may cause myocyte loss and expansion of the myocardial extracellular volume (ECV) fraction by oedema and fibrosis. We tested the hypotheses that adjuvant treatment for early breast cancer with the anthracycline epirubicin is dose dependently associated with increased ECV fraction and total ECV, as well as reduced total myocardial cellular volume, and that these changes could be prevented by concomitant angiotensin or beta-adrenergic blockade. Methods and results: PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA) was a 2 × 2 factorial, placebo-controlled, double-blinded trial of candesartan and metoprolol. Sixty-nine women had valid ECV measurements. ECV fraction, total ECV, and total cellular volume were measured by cardiovascular magnetic resonance before and at the completion of anthracycline therapy. ECV fraction increased from 27.5 ± 2.7% to 28.6 ± 2.9% (P = 0.002). A cumulative doxorubicin equivalent dose of 268 mg/m2 was associated with greater increase in ECV fraction than doses <268 mg/m2 (mean change 3.4% [95% confidence interval (CI) 1.2, 5.5] vs. 0.7% [95% CI 0.0, 1.5], P = 0.006), as well as greater increase in total ECV (1.9 mL [95% CI 0.4, 3.5] vs. 0.1 mL [95% CI -0.6, 0.8], P = 0.04). In patients receiving candesartan, total cellular volume decreased (-3.5 mL [95% CI - 4.7, -2.2], P < 0.001) while in patients not receiving candesartan, it remained unchanged (P = 0.45; between group difference P = 0.003). Conclusions: Anthracycline therapy is associated with dose-dependent increase in ECV fraction and total ECV. Concomitant treatment with candesartan reduces left ventricular total cellular volume.

• Gulati, Geeta; Heck, Siri Lagethon; Røsjø, Helge; Ree, Anne Hansen; HOFFMANN, PAVEL & Hagve, Tor-Arne [Vis alle 11 forfattere av denne artikkelen] (2017). Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: Results from the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) study. Journal of the American Heart Association (JAHA). ISSN 2047-9980. 6(11). doi: 10.1161/JAHA.117.006513. Fulltekst i vitenarkiv
• Østrup, Olga; Dagenborg, Vegar Johansen; Rødland, Einar Andreas; Skarpeteig, Veronica ; Silwal-Pandit, Laxmi & Grzyb, Krzysztof [Vis alle 13 forfattere av denne artikkelen] (2017). Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. OncoTarget. ISSN 1949-2553. 8(44), s. 76290–76304. doi: 10.18632/oncotarget.19350. Fulltekst i vitenarkiv
• Bakke, Kine Mari; Hole, Knut Håkon; Dueland, Svein; Kotanska-Grøholt, Krystyna; Flatmark, Kjersti & Ree, Anne Hansen [Vis alle 8 forfattere av denne artikkelen] (2017). Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival. Acta Oncologica. ISSN 0284-186X. 56(6), s. 813–818. doi: 10.1080/0284186X.2017.1287951. Fulltekst i vitenarkiv
• Ree, Anne Hansen; Russnes, Hege Elisabeth Giercksky; Heinrich, Daniel; Dueland, Svein; Pedersen, Kjetil Boye & Nygaard, Vigdis [Vis alle 33 forfattere av denne artikkelen] (2017). Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. ESMO Open. ISSN 2059-7029. 2(2), s. 1–10. doi: 10.1136/esmoopen-2017-000158. Fulltekst i vitenarkiv
• Kalanxhi, Ert; Risberg, Karianne; Barua, Imon Shoumitra; Dueland, Svein; Waagene, Stein & Andersen, Solveig Norheim [Vis alle 11 forfattere av denne artikkelen] (2017). Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy. Cancer research and treatment : official journal of Korean Cancer Association. ISSN 1598-2998. 49(2), s. 374–386. doi: 10.4143/crt.2016.080. Fulltekst i vitenarkiv
• Grøvik, Endre; Redalen, Kathrine Røe; Storås, Tryggve; Negard, Anne; Holmedal, Stein Harald & Ree, Anne Hansen [Vis alle 9 forfattere av denne artikkelen] (2017). Dynamic multi-echo DCE- and DSC-MRI in rectal cancer: Low primary tumor Ktrans and ΔR2* peak are significantly associated with lymph node metastasis. Journal of Magnetic Resonance Imaging. ISSN 1053-1807. 46(1), s. 194–206. doi: 10.1002/jmri.25566. Fulltekst i vitenarkiv
• Dueland, Svein; Ree, Anne Hansen; Kotanska-Grøholt, Krystyna; Sælen, Marie Grøn; Folkvord, Sigurd & Hole, Knut Håkon [Vis alle 12 forfattere av denne artikkelen] (2016). Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome. Clinical Oncology. ISSN 0936-6555. 28(8), s. 532–539. doi: 10.1016/j.clon.2016.01.014.
• Flatmark, Kjersti; Sælen, Marie Grøn; Hole, Knut Håkon; Abrahamsen, Torveig Weum; Fleten, Karianne Giller & Hektoen, Helga [Vis alle 10 forfattere av denne artikkelen] (2016). Individual tumor volume responses to short-course oxaliplatin containing induction chemotherapy in locally advanced rectal cancer – Targeting the tumor for radiation sensitivity? Radiotherapy and Oncology. ISSN 0167-8140. 119(3), s. 505–511. doi: 10.1016/j.radonc.2016.02.020. Vis sammendrag

  Background Neoadjuvant treatment of locally advanced rectal cancer (LARC) involves chemoradiotherapy (CRT), which may cause significant toxicity, and the potential role and sequential placement of neoadjuvant chemotherapy (NACT) relative to CRT is under debate. Patients and methods In a non-randomized study of 72 LARC patients, short-course oxaliplatin-containing NACT was administered prior to CRT. Tumor volumes were calculated from magnetic resonance images before and after NACT, and four weeks after CRT, and associations between tumor volume responses and outcome were analyzed. Additionally, the impact of oxaliplatin exposure on radiosensitivity was examined in colorectal carcinoma cell lines. Results All tumors except one responded to NACT, with better responses in T3 than T4 cases, and 69/72 patients obtained additional tumor volume reduction after subsequent CRT. However, no associations were found between tumor volume reduction and long-term outcome. Of note, oxaliplatin-resistant cells were significantly more radiosensitive than the oxaliplatin-sensitive counterparts. Conclusions Oxaliplatin-containing NACT led to substantial tumor volume reduction with particularly good responses in T3 cases. NACT did not impede subsequent CRT response, and experimental results rather suggested enhanced radiosensitivity in oxaliplatin-exposed cells, encouraging studies to explore the administration of NACT prior to CRT. Data are still lacking to support omitting radiation in LARC management.

• Jonsson, Marte; Ragnum, Harald Bull; Halle, Cathinka Lønning; Yeramian, Andree; Clancy, Trevor & Frikstad, Kari-Anne [Vis alle 12 forfattere av denne artikkelen] (2016). Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition. British Journal of Cancer. ISSN 0007-0920. 115(8), s. 929–939. doi: 10.1038/bjc.2016.278.
• Risberg, Karianne; Redalen, Kathrine Røe; Sønstevold, Linda; Bjørnetrø, Tonje; Sølvernes, Janne & Ree, Anne Hansen (2016). Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. BMC Cancer. ISSN 1471-2407. 16:531, s. 1–11. doi: 10.1186/s12885-016-2600-y. Vis sammendrag

  Background The use of targeted agents to impel dual inhibition of anti-apoptotic mechanisms and mTOR-mediated pro-survival signaling in colorectal carcinoma (CRC) cell lines with KRAS or BRAF mutation has been shown to induce apoptosis, a timely result given CRC entities harboring such mutations are in need of new therapies. Since CRC comprises heterogeneous tumors with predominant hypoxic components, we investigated effects of an inhibitor of anti-apoptotic Bcl-2 family proteins (ABT-737) in combination with an mTOR inhibitor (AZD8055)—collectively referred to as combo-Rx, in hypoxic CRC cell lines. Methods Cell viability measures, expression of proteins implicated in apoptosis and MAPK/PI3K-AKT/mTOR pathway signaling, and profiling of composite kinase activities were undertaken in a panel of 14 cell lines. Results In hypoxic conditions, combo-Rx suppressed viability of 13 of the cell lines, albeit ABT-737 did not significantly potentiate the inhibitory effect of single-agent AZD8055 in six of the models. Hypoxic KRAS/PIK3CA-mutant HCT-116 and HCT-15 cell lines (both with low endogenous expression of the anti-apoptotic Mcl-1 protein and showing augmented inhibition of viability following the addition of ABT-737 to AZD8055) responded to combo-Rx by induction of apoptosis but with the simultaneous strong Mcl-1 up-regulation and activation of MAPK/PI3K-conducted signaling. In contrast, in hypoxic KRAS-mutant LoVo (devoid of PIK3CA mutation), BRAF/PIK3CA-mutant RKO, and wild-type Colo320DM cell lines (all with high endogenous Mcl-1 expression and being resistant to the additional effect of ABT-737 to AZD8055), combo-Rx did not elicit apoptotic or pro-survival responses. Conclusions The concurrent inhibition of anti-apoptotic proteins and mTOR-mediated signaling in hypoxic KRAS/PIK3CA-mutant CRC cell lines resulted in pro-survival responses in parallel with the intended anti-proliferative effects, a finding that should be of note if considering combinatory targeting of multiple pathways in this CRC entity.

• Kalanxhi, Ert; Hektoen, Helga; Meltzer, Sebastian; Dueland, Svein; Flatmark, Kjersti & Ree, Anne Hansen (2016). Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening. BMC Cancer. ISSN 1471-2407. 16:536. doi: 10.1186/s12885-016-2601-x.
• Gulati, Geeta; Heck, Siri Lagethon; Ree, Anne Hansen; HOFFMANN, PAVEL; Schulz-Menger, Jeanette & Fagerland, Morten [Vis alle 15 forfattere av denne artikkelen] (2016). Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. European Heart Journal. ISSN 0195-668X. 37(21), s. 1671–1680. doi: 10.1093/eurheartj/ehw022.
• Meltzer, Sebastian; Kalanxhi, Ert; Hektoen, Helga; Dueland, Svein; Flatmark, Kjersti & Redalen, Kathrine Røe [Vis alle 7 forfattere av denne artikkelen] (2016). Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer. OncoTarget. ISSN 1949-2553. 7(23), s. 34907–34917. doi: 10.18632/oncotarget.8995. Vis sammendrag

  In colorectal cancer, immune effectors may be determinative for disease outcome. Following curatively intended combined-modality therapy in locally advanced rectal cancer metastatic disease still remains a dominant cause of failure. Here, we investigated whether circulating immune factors might correlate with outcome. An antibody array was applied to assay changes of approximately 500 proteins in serial serum samples collected from patients during oxaliplatin-containing induction chemotherapy and sequential chemoradiotherapy before final pelvic surgery. Array data was analyzed by the Significance Analysis of Microarrays software and indicated significant alterations in serum osteoprotegerin (TNFRSF11B) during the treatment course, which were confirmed by osteoprotegerin measures using a single-parameter immunoassay. Patients experiencing increase in circulating osteoprotegerin during the chemotherapy had significantly better 5-year progression-free survival than those without increase (78% versus 48%; P = 0.009 by log-rank test). Hence, systemic release of this soluble tumor necrosis factor decoy receptor following the induction phase of neoadjuvant therapy was associated with favorable long-term outcome in patients given curatively intended chemoradiotherapy and surgery but with metastatic disease as the main adverse event. This finding suggests that osteoprotegerin may mediate or reflect systemic anti-tumor immunity invoked by combined-modality therapy in locally advanced rectal cancer.

• Redalen, Kathrine Røe; Sitter, Beathe; Bathen, Tone Frost; Kotanska-Grøholt, Krystyna; Hole, Knut Håkon & Dueland, Svein [Vis alle 9 forfattere av denne artikkelen] (2016). High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer. Radiotherapy and Oncology. ISSN 0167-8140. 118(2), s. 393–398. doi: 10.1016/j.radonc.2015.11.031.

Se alle arbeider i Cristin

• Bakke, Kine Mari; Meltzer, Sebastian; Grøvik, Endre; Negård, Anne; Holmedal, Stein Harald & Lyckander, Lars Gustav [Vis alle 11 forfattere av denne artikkelen] (2022). Imaging the tumor microenvironment in rectal cancer: Decline in tumor blood flow (BF) during neoadjuvant treatment predicts excellent outcome. Cancer Research. ISSN 0008-5472. 82. doi: 10.1158/1538-7445.AM2022-5269.
• Meltzer, Sebastian; Negård, Anne; Hamre, Hanne Mari; Kersten, Christian; Hofsli, Eva & Guren, Marianne Grønlie [Vis alle 9 forfattere av denne artikkelen] (2022). Early radiologic signal of nivolumab responsiveness after short-course oxaliplatin-based chemotherapy in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
• Kalveland, Julie; Tasken, Kjetil; Ree, Anne Hansen & Opdalshei, Ole Alexander (2022). Studie: Presisjonsmedisin dobbelt så dyr som annen behandling av kreftpasienter i siste fase. [Avis]. Dagens Medisin.
• Tasken, Kjetil; Russnes, Hege Elisabeth Giercksky; Aas, Eline; Bjørge, Line; Blix, Egil Støre & Ahlquist, Terje C. [Vis alle 116 forfattere av denne artikkelen] (2022). A national precision cancer medicine implementation initiative for Norway. Nature Medicine. ISSN 1078-8956. 28(5), s. 885–887. doi: 10.1038/s41591-022-01777-4.
• Larsen, Trine-Lise; Garresori, Herish; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege & Jacobsen, Eva-Marie [Vis alle 15 forfattere av denne artikkelen] (2022). “Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up”: Reply. Journal of Thrombosis and Haemostasis. ISSN 1538-7933. 20(8), s. 1937–1939. doi: 10.1111/jth.15774.
• Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne & Berg, Thomas [Vis alle 53 forfattere av denne artikkelen] (2022). Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway (Journal of Translational Medicine, (2022), 20, 1, (225), 10.1186/s12967-022-03432-5). Journal of Translational Medicine. ISSN 1479-5876. 20(1). doi: 10.1186/s12967-022-03518-0.
• Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne & Berg, Thomas [Vis alle 53 forfattere av denne artikkelen] (2022). Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. Journal of Translational Medicine. ISSN 1479-5876. 20(1), s. 1–11. doi: 10.1186/s12967-022-03432-5. Fulltekst i vitenarkiv Vis sammendrag

  Background Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed attention has arisen due to recent advancements in cancer diagnostics including access to high-throughput sequencing of tumour tissue. Targeted therapies interfering with cancer specific pathways have been developed and approved for subgroups of patients. These drugs might just as well be efficient in other diagnostic subgroups, not investigated in pharma-led clinical studies, but their potential use on new indications is never explored due to limited number of patients. Methods In this national, investigator-initiated, prospective, open-label, non-randomized combined basket- and umbrella-trial, patients are enrolled in multiple parallel cohorts. Each cohort is defined by the patient’s tumour type, molecular profile of the tumour, and study drug. Treatment outcome in each cohort is monitored by using a Simon two-stage-like ‘admissible’ monitoring plan to identify evidence of clinical activity. All drugs available in IMPRESS-Norway have regulatory approval and are funded by pharmaceutical companies. Molecular diagnostics are funded by the public health care system.

• Ree, Anne Hansen; Hamre, Hanne Mari; Kersten, Christian; Hofsli, Eva; Guren, Marianne Grønlie & Sørbye, Halfdan [Vis alle 10 forfattere av denne artikkelen] (2021). Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study.
• Ree, Anne Hansen (2021). Presisjonsmedisin ved kreft – førebels føremålstenleg for dei få. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 141(5), s. 1–5. doi: 10.4045/tidsskr.20.0980.
• Ree, Anne Hansen (2021). Precision cancer medicine – still expedient for the few. Tidsskrift for Den norske legeforening. ISSN 0029-2001. doi: 10.4045/tidsskr.20.0980.
• Knuth, Franziska Hanna; Adde, Ingvild Askim; Huynh, Bao Ngoc; Grøndahl, Aurora Rosvoll; Winter, René & Negård, Anne [Vis alle 15 forfattere av denne artikkelen] (2021). MRI-based automatic segmentation of rectal cancer using 2D U-Net on two independent cohorts.
• Ree, Anne Hansen; Bousquet, Anna Paula; Bjørnetrø, Tonje; Fuglestad, Anniken Jørlo; Lüders, Torben & Esbensen, Qin Ying [Vis alle 12 forfattere av denne artikkelen] (2020). Circulating mitochondrial DNA (mtDNA) variants to predict metastatic progression of rectal cancer.
• Meltzer, Sebastian; Bakke, Kine Mari; Lund Rød, Karina; Dueland, Svein; Flatmark, Kjersti & Kristensen, Annette Torgunrud [Vis alle 12 forfattere av denne artikkelen] (2019). Gender disparities in outcome after neoadjuvant chemoradiotherapy for locally advanced rectal cancer are associated with hemodynamic differences.
• Meltzer, Sebastian; Redalen, Kathrine; Dueland, Svein; Kristensen, Annette Torgunrud; Solbakken, Arne Mide & Flatmark, Kjersti [Vis alle 7 forfattere av denne artikkelen] (2019). Circulating angiogenic factors predict metastatic liver progression in rectal cancer patients given curative-intent oxaliplatin-containing neoadjuvant therapy.
• Bakke, Kine Mari; Meltzer, Sebastian; Grøvik, Endre; Negård, Anne; Holmedal, Stein Harald & Ree, Anne Hansen [Vis alle 8 forfattere av denne artikkelen] (2019). Tumour blood perfusion from baseline contrast-based MRI predicts radiation outcome in rectal cancer.
• Frøyen, Elin Agathe; Lyckander, Lars Gustav; Grandal, Ole Jacob; Lunder, Aida Kapic; Meltzer, Sebastian & Redalen, Kathrine [Vis alle 8 forfattere av denne artikkelen] (2019). MRI of Extramural Venous Invasion in rectal cancer: assessment of the interobserver agreement and comparison with histopathology stained with hematoxylin/eosin and elastin.
• Bjørnetrø, Tonje; Risberg, Karianne; Meltzer, Sebastian; Samiappan, Rampradeep; Lyckander, Lars Gustav & Jegerschöld, Caroline [Vis alle 10 forfattere av denne artikkelen] (2017). Low release of exosomal miR-663a from hypoxic tumor cells and poor tumor response to neoadjuvant radiotherapy in rectal cancer patients. Cancer Research. ISSN 0008-5472. 77, s. 4514–4514. doi: 10.1158/1538-7445.AM2017-4514.
• Bousquet, Paula; Meltzer, Sebastian; Sønstevold, Linda; Esbensen, Qin Ying; Lyckander, Lars Gustav & Dueland, Svein [Vis alle 10 forfattere av denne artikkelen] (2017). Reactive oxygen species (ROS) and mitochondrial DNA (mtDNA) damage in tumor hypoxia, poor radiotherapy response, and metastatic progression of rectal cancer. Cancer Research. ISSN 0008-5472. 77, s. 1782–1782. doi: 10.1158/1538-7445.AM2017-1782.
• Meltzer, Sebastian; Lyckander, Lars Gustav; Ree, Anne Hansen & Redalen, Kathrine Røe (2017). Circulating angiogenesis factors predicting poor chemoradiotherapy outcome in rectal cancer.
• Grøvik, Endre; Redalen, Kathrine Røe; Storås, Tryggve; Holmedal, Stein Harald; Negard, Anne & Ree, Anne Hansen [Vis alle 9 forfattere av denne artikkelen] (2017). Improved sensitivity for rectal cancer differentiation by T2*-correction in DCE-MRI.
• Bakke, Kine Mari; Hole, Knut Håkon; Dueland, Svein; Grøholt, Krystyna Kotanska; Ree, Anne Hansen & Flatmark, Kjersti [Vis alle 8 forfattere av denne artikkelen] (2017). Diffusion-weighted MRI of rectal cancer: baseline tumour perfusion fraction predicts chemoradiotherapy response and survival.
• Barua, Imon Shoumitra; Ree, Anne Hansen; Sønstevold, Linda; Redalen, Kathrine Røe & Kalanxhi, Ert (2017). Mechanisms of normal tissue toxicity from SAHA - an HDAC inhibitor and radiosensitizer .
• Meltzer, Sebastian; Ree, Anne Hansen; Lyckander, Lars Gustav & Redalen, Kathrine Røe (2017). Circulating exosomal miRNA related to chemoradiotherapy outcome in locally advanced rectal cancer.
• Ree, Anne Hansen (2016). Kreftbehandling - tilbake til framtida : er stråle- og kjemoterapi effektiv immunterapi ved kreft? Tidsskrift for Den norske legeforening. ISSN 0029-2001. 136(19), s. 1605–1605. doi: 10.4045/tidsskr.16.0630.
• Bjørnetrø, Tonje; Ree, Anne Hansen; Redalen, Kathrine Røe & Risberg, Karianne (2016). Exosomes from hypoxic colorectal cancer cells – miRNA cargo as indicator of adverse CRC biology?
• Bakke, Kine Mari; Seierstad, Therese; Hole, Knut Håkon; Dueland, Svein; Flatmark, Kjersti & Ree, Anne Hansen [Vis alle 7 forfattere av denne artikkelen] (2016). Histogram analysis of ADCs from DWMRI predicts tumour response and survival for rectal cancer.
• Redalen, Kathrine Røe; Sitter, Beathe; Bathen, Tone Frost; Grøholt, Krystyna Kotanska; Hole, Knut Håkon & Dueland, Svein [Vis alle 9 forfattere av denne artikkelen] (2016). High tumour glycine concentration – an adverse prognostic factor in locally advanced rectal cancer.
• Bakke, Kine Mari; Hole, Knut Håkon; Dueland, Svein; Flatmark, Kjersti; Ree, Anne Hansen & Seierstad, Therese [Vis alle 7 forfattere av denne artikkelen] (2016). Tumour perfusion estimated from diffusion-weighted MRI of rectal cancer – an indirect marker of tumour hypoxia?
• Heck, Siri Lagethon; Gulati, Geeta; HOFFMANN, PAVEL; von Knobelsdorff-Brenkenhoff, Florian; Storås, Tryggve & Ree, Anne Hansen [Vis alle 11 forfattere av denne artikkelen] (2016). Effects of Candesartan and Metoprolol on Myocardial Mass, Edema, and Fibrosis During Anthracycline Treatment in Early Breast Cancer: APRADA-CMR substudy.
• Meltzer, Sebastian; Kalanxhi, Ert; Dueland, Svein; Flatmark, Kjersti; Redalen, Kathrine Røe & Ree, Anne Hansen (2016). Oxaliplatin-induced immune factors and long-term disease control in rectal cancer - a reflection of immunogenic tumor cell death?
• Gulati, Geeta; Heck, Siri Lagethon; Geisler, Jürgen; Gravdehaug, Berit; Ree, Anne Hansen & HOFFMANN, PAVEL [Vis alle 9 forfattere av denne artikkelen] (2016). Atrio-ventricular plane excursion is impaired after ten weeks of anthracycline treatment in breast cancer patients; Data from the PRADA-study.
• Gulati, Geeta; Heck, Siri Lagethon; Geisler, Jürgen; Gravdehaug, Berit; HOFFMANN, PAVEL & Steine, Kjetil [Vis alle 9 forfattere av denne artikkelen] (2016). Troponin I and Cardiac Function During Breast Cancer Therapy in Human Epidermal Growth Factor Receptor 2 Positive and Negative Patients: Results from the PRADA Study.
• Gulati, Geeta; Heck, Siri Lagethon; Geisler, Jürgen; Fagerland, Morten; HOFFMANN, PAVEL & Gravdehaug, Berit [Vis alle 10 forfattere av denne artikkelen] (2016). Effect of candesartan and metoprolol on subclinical myocardial injury during anthracycline therapy: data from the prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA) study.
• Gulati, Geeta; Heck, Siri Lagethon; HOFFMANN, PAVEL; Ree, Anne Hansen; Schulz-Menger, Jeanette & von Knobelsdorff-Brenkenhoff, Florian [Vis alle 12 forfattere av denne artikkelen] (2016). Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Primary Results of a Randomized, 2 x 2 Factorial, Placebo-Controlled, Double-Blind Clinical Trial. Circulation. ISSN 0009-7322.
• Sivarajah, Nirujah; Ree, Anne Hansen; Kalanxhi, Ert; Redalen, Kathrine Røe & Risberg, Karianne (2015). Identification of optimal culturing conditions for studying exosomes from normoxic and hypoxic colorectal cancer cell lines.
• Gulati, Geeta; Heck, Siri Lagethon; Ree, Anne Hansen; Bratland, Åse; Steine, Kjetil & Schulz-Menger, Jeanette [Vis alle 11 forfattere av denne artikkelen] (2015). Abstract CT321: Prevention of cardiac dysfunction during adjuvant breast cancer therapy: the PRADA study. Cancer Research. ISSN 0008-5472.
• Bakke, Kine Mari; Seierstad, Therese; Hole, Knut Håkon; Ree, Anne Hansen & Redalen, Kathrine Røe (2015). Histogram analysis of apparent diffusion coefficients from diffusion-weighted MRI during neoadjuvant treatment of locally advanced rectal cancer predicts histologic tumor response and survival.
• Meltzer, Sebastian; Ree, Anne Hansen & Redalen, Kathrine Røe (2015). The OxyTarget study – Functional MRI of Hypoxia-Mediated Rectal Cancer Aggressiveness.
• Meltzer, Sebastian; Kalanxhi, Ert; Hektoen, Helga; Dueland, Svein; Flatmark, Kjersti & Redalen, Kathrine Røe [Vis alle 7 forfattere av denne artikkelen] (2015). Circulating tumor necrosis factor receptor (TNFR) proteins in systemic disease outcome to combined-modality radiotherapy in rectal cancer.
• Barua, Imon Shoumitra; Kalanxhi, Ert; Ree, Anne Hansen & Redalen, Kathrine Røe (2015). Histone deacetylase inhibitors in combined-modality cancer treatment – experimental studies of normal tissue effects.
• Seierstad, Therese; Hole, Knut Håkon; Grøholt, Krystyna Kotanska; Dueland, Svein; Ree, Anne Hansen & Flatmark, Kjersti [Vis alle 7 forfattere av denne artikkelen] (2015). Prediction of response to neoadjuvant chemotherapy followed by chemoradiotherapy in rectal cancer by MRI volumetry. Radiotherapy and Oncology. ISSN 0167-8140. 115.
• Kalanxhi, Ert; Hektoen, Helga; Meltzer, Sebastian; Dueland, Svein; Redalen, Kathrine Røe & Flatmark, Kjersti [Vis alle 7 forfattere av denne artikkelen] (2015). Circulating proteins in response to combined-modality therapy in locally advanced rectal cancer identified by antibody array screening. Cancer Research. ISSN 0008-5472. 75(15). doi: 10.1158/1538-7445.AM2015-571.
• Hektoen, Helga; Ree, Anne Hansen; Redalen, Kathrine Røe & Flatmark, Kjersti (2015). Translational studies of microenvironmental factors in rectal cancer with emphasis on tumor hypoxia. Akademika forlag. ISSN 978-82-8333-077-9.

Se alle arbeider i Cristin